Last reviewed · How we verify

NCT03052296

BIOLUX P-III SPAIN All-Comers Registry

Completed Last updated 5 August 2021
What this trial tests

trial testing Passeo-18 Lux DCB in Peripheral Arterial Disease in 44 participants. Completed in 5 November 2019.

Timeline
22 March 2017
Primary endpoint
5 November 2019
5 November 2019

Quick facts

Lead sponsorBiotronik AG
StatusCompleted
Study typeOBSERVATIONAL
Enrollment44
Start date22 March 2017
Primary completion5 November 2019
Estimated completion5 November 2019
Sites5 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Biotronik AG

Who can join

18 and older, any sex, with Peripheral Arterial Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the BIOLUX P-III Spain registry is to further investigate the safety and clinical performance of the Passeo-18 Lux Drug Coated Balloon in the treatment of long atherosclerotic femoropoliteal artery lesions in daily clinical practice

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Passeo-18 Lux DCB

Trials testing the same drug.

Other recruiting trials for Peripheral Arterial Disease

Currently open trials in the same condition.

Other Biotronik AG trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03052296.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing